5.65
price up icon3.86%   0.21
pre-market  Pre-mercato:  5.68   0.03   +0.53%
loading
Precedente Chiudi:
$5.44
Aprire:
$5.53
Volume 24 ore:
1.75M
Relative Volume:
0.80
Capitalizzazione di mercato:
$484.52M
Reddito:
$42.51M
Utile/perdita netta:
$-116.49M
Rapporto P/E:
-5.0446
EPS:
-1.12
Flusso di cassa netto:
$-120.82M
1 W Prestazione:
+13.68%
1M Prestazione:
+122.44%
6M Prestazione:
+80.51%
1 anno Prestazione:
-30.29%
Intervallo 1D:
Value
$5.445
$5.96
Intervallo di 1 settimana:
Value
$4.60
$5.96
Portata 52W:
Value
$1.03
$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name
Nome
Tango Therapeutics Inc
Name
Telefono
(857) 320-4900
Name
Indirizzo
201 BROOKLINE AVENUE, BOSTON
Name
Dipendente
155
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-06
Name
Ultimi documenti SEC
Name
TNGX's Discussions on Twitter

Confronta TNGX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
TNGX
Tango Therapeutics Inc
5.65 484.52M 42.51M -116.49M -120.82M -1.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-07-17 Iniziato Jefferies Buy
2024-04-04 Iniziato Cantor Fitzgerald Overweight
2024-02-12 Iniziato Piper Sandler Overweight
2023-12-08 Iniziato B. Riley Securities Buy
2022-10-20 Aggiornamento H.C. Wainwright Neutral → Buy
2021-09-20 Iniziato SVB Leerink Outperform
Mostra tutto

Tango Therapeutics Inc Borsa (TNGX) Ultime notizie

pulisher
Jun 16, 2025

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Jun 16, 2025
pulisher
Jun 14, 2025

Tango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trials - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Two Sigma Investments LP Sells 23,166 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

B. Riley Increases Earnings Estimates for Tango Therapeutics - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

What is B. Riley’s Forecast for TNGX Q2 Earnings? - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Makes New $40,000 Investment in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Takes Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock Holdings Increased by Bank of America Corp DE - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

11,198 Shares in Tango Therapeutics, Inc. (NASDAQ:TNGX) Acquired by Ameriprise Financial Inc. - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Millennium Management LLC Invests $771,000 in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Tango Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Tango Therapeutics: PRMT5 Data Readout Due In 2025 Is Critical (NASDAQ:TNGX) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Sold by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

TNGX Stock Price and Chart — NASDAQ:TNGX - TradingView

Jun 06, 2025
pulisher
Jun 04, 2025

Deutsche Bank AG Boosts Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Jane Street Group LLC Purchases 44,465 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Tango Therapeutics To Present At Goldman Sachs Global Healthcare Conference On June 10, 2025 - Nasdaq

Jun 02, 2025
pulisher
May 27, 2025

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

D. E. Shaw & Co. Inc. Takes $355,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 27, 2025
pulisher
May 27, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Northern Trust Corp - Defense World

May 27, 2025
pulisher
May 22, 2025

Tango Therapeutics doses first subject in trial for MTAP-deleted tumours - Yahoo Finance

May 22, 2025
pulisher
May 21, 2025

Tango Therapeutics starts trial for brain cancer drug By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics starts trial for brain cancer drug - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics, Inc. Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients with MTAP-Deleted Glioblastoma and Other Solid Tumors - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Doses First Patient for Phase 1/2 Trial to Treat Brain Cancer - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

TNGX Initiates Phase 1/2 Trial for MTAP-Deleted Tumors | TNGX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Tango Therapeutics Announces First Patient Dosed in TNG456 - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Tango Launches Phase 1/2 Trial for Brain Cancer Drug: New Hope for Deadly Glioblastoma Treatment - Stock Titan

May 21, 2025
pulisher
May 18, 2025

Cantor Fitzgerald Issues Positive Estimate for TNGX Earnings - Defense World

May 18, 2025
pulisher
May 16, 2025

Leerink Partnrs Analysts Boost Earnings Estimates for TNGX - Defense World

May 16, 2025
pulisher
May 15, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Dimensional Fund Advisors LP Purchases 302,087 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 15, 2025
pulisher
May 15, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Tango Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 14, 2025
pulisher
May 14, 2025

Barclays Remains a Buy on Tango Therapeutics (TNGX) - The Globe and Mail

May 14, 2025
pulisher
May 13, 2025

Tango Therapeutics Extends Cash Runway Amid Clinical Progress - TipRanks

May 13, 2025
pulisher
May 12, 2025

Tango Therapeutics (TNGX) Plans $400 Million Mixed Securities Sh - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Files For Mixed Shelf Of Up To $400 Million - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Mi - GuruFocus

May 12, 2025
pulisher
May 12, 2025

TNGX Reports Q1 Revenue Miss, Advances Cancer Treatments | TNGX Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Inc (TNGX) Q1 2025 Earnings: EPS of -$0.36 Misses Estimate, Revenue Falls Short at $5.4 Million - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics, Inc. SEC 10-Q Report - TradingView

May 12, 2025
pulisher
May 12, 2025

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewswire

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Has $307,000 Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

May 12, 2025
pulisher
May 10, 2025

Tango Therapeutics (TNGX) to Release Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Insights into Tango Therapeutics's Upcoming Earnings - Nasdaq

May 09, 2025
pulisher
May 09, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Consensus Rating of “Buy” by Analysts - Defense World

May 09, 2025

Tango Therapeutics Inc Azioni (TNGX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Tango Therapeutics Inc Azioni (TNGX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Barry Douglas
General Counsel
Feb 05 '25
Sale
3.16
2,556
8,081
66,014
Beckman Daniella
Chief Financial Officer
Feb 04 '25
Sale
2.99
4,284
12,801
154,232
Beckman Daniella
Chief Financial Officer
Feb 05 '25
Sale
3.16
3,948
12,481
150,284
Crystal Adam
See Remarks
Feb 04 '25
Sale
2.99
7,432
22,207
165,061
Crystal Adam
See Remarks
Feb 05 '25
Sale
3.16
6,851
21,659
158,210
Weber Barbara
Chief Executive Officer
Feb 04 '25
Sale
2.99
9,778
29,217
1,631,264
Weber Barbara
Chief Executive Officer
Feb 05 '25
Sale
3.16
9,013
28,494
1,622,251
Rothenberg Mace
Director
Nov 18 '24
Buy
3.78
10,000
37,800
31,250
Rothenberg Mace
Director
Nov 14 '24
Buy
3.62
10,000
36,200
21,250
EcoR1 Capital, LLC
10% Owner
Nov 06 '24
Sale
3.28
1,494,558
4,896,023
11,836,178
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):